IL37 and hepatocellular carcinoma: TAMs may also release other ILs such as IL-6, IL-17, and IL-23 that can support tumor growth and progression as shown in models of colon cancer and hepatocellular carcinoma, in which tumor progression was associated with activation of the STAT3 signaling pathway (95, 96).